Results 61 to 70 of about 179,934 (163)

TP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 Cases

open access: yesTurkish Journal of Hematology, 2017
Objective: Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. The aim of this study is to find out if the extent of proliferation centers or the immunohistochemical expression of p53 is related to disease ...
İbrahim Kulaç   +4 more
doaj   +1 more source

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

open access: yesCancer Management and Research, 2020
Yan Qin,1,* Shiyu Jiang,1,* Peng Liu,1 Jianliang Yang,1 Sheng Yang,1 Xiaohui He,1 Shengyu Zhou,1 Lin Gui,1 Jing Lin,2 Xinhua Du,3 Yuting Yi,3 Yan Sun,1 Yuankai Shi1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center
Qin Y   +12 more
doaj  

A role for p53 in telomere protection

open access: yesMolecular & Cellular Oncology, 2017
Telomeres cap the ends of chromosomes and are crucial for genome stability. The p53 protein (TP53) is a vital tumor suppressor, activating the transcription of numerous genes in response to cell stress.
Stephen Tutton, Paul M. Lieberman
doaj   +1 more source

Current Issues in Carcinogenesis

open access: yesКлиническая онкогематология, 2019
The review presents current data on the major pathogenetic mechanisms underlying uncontrolled growth and dissemination of tumor and its resistance to conventional treatment.
Irina Viktorovna Vysotskaya   +5 more
doaj   +1 more source

TP53 Mutations in Nonsmall Cell Lung Cancer [PDF]

open access: yes, 2011
The tumor suppressor gene TP53 is frequently mutated in human cancers. Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells.
Akira Mogi, Hiroyuki Kuwano
core   +1 more source

Integrating mutation variant allele frequency into clinical practice in myeloid malignancies

open access: yesHematology/Oncology and Stem Cell Therapy, 2016
Hematologic myeloid neoplasms represent a heterogeneous group of disorders with defined clinical and pathologic characteristics. However, intensive investigation into the genetic abnormalities of these diseases has not only significantly advanced our ...
David A. Sallman, Eric Padron
doaj   +1 more source

A Molecular and Computational Study on the Effects of 5-Fluorouracil, and Dicyclomine on AGS Cells: Regulation of P53 and SNAIL2 Pathways [PDF]

open access: yesPharmaceutical Sciences
Background: 5-Fluorouracil (5-FU) is commonly used to inhibit gastric cancer (GC) cell growth, but its clinical effectiveness is frequently limited by chemoresistance.
Fariba Ghodrati   +7 more
doaj   +1 more source

Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis

open access: yes, 2018
Zhiyong Dong,1,2,* Longzhi Zheng,2,* Weimin Liu,1 Cunchuan Wang1 1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China; 2Department of Surgery, The Affiliated Hospital of Putian University, Putian ...
Dong ZY, Wang C, Zheng L, Liu W
core  

TP53 and Breast Cancer

open access: yes, 2020
Norway For the p53 Special Issue The TP53 gene (p53) is found altered in breast carcinomas in approximately 20-40% of all cases depending on tumor size and stage of the disease. It seems to be an early event in breast tumorigenesis. Several polymorphisms
Anne-Lise Brresen-Dale
core  

Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.

open access: yes, 2021
a, Cancer dependency map (DepMap) data for ARID1A wild-type cell lines, measuring ARID1A knockout viability effect on TP53 wild-type vs. mutant lines. Statistic is unpaired, two-tailed Wilcoxon test.
Ken Lin (9358913)   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy